These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819 [TBL] [Abstract][Full Text] [Related]
3. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis. Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979 [TBL] [Abstract][Full Text] [Related]
4. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720 [TBL] [Abstract][Full Text] [Related]
5. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study. Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755 [TBL] [Abstract][Full Text] [Related]
6. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
7. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744 [TBL] [Abstract][Full Text] [Related]
9. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O; Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595 [TBL] [Abstract][Full Text] [Related]
11. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583 [TBL] [Abstract][Full Text] [Related]
12. Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion? Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA Ann Surg Oncol; 2023 Apr; 30(4):2486-2493. PubMed ID: 36484904 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
14. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702 [TBL] [Abstract][Full Text] [Related]
15. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907 [TBL] [Abstract][Full Text] [Related]
17. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455 [TBL] [Abstract][Full Text] [Related]
18. Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre. Hassan S; Dritsas S; O'Dwyer ST; Aziz O; Sutton P; Wang X; Fish R; Eur J Surg Oncol; 2023 Sep; 49(9):106924. PubMed ID: 37179147 [TBL] [Abstract][Full Text] [Related]
19. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M; JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455 [TBL] [Abstract][Full Text] [Related]
20. Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin. Papageorgopoulou C; Nikolakopoulos K; Seretis C Chirurgia (Bucur); 2022 Jun; 117(3):266-277. PubMed ID: 35792537 [No Abstract] [Full Text] [Related] [Next] [New Search]